Antihypertensive medications and risk of community-acquired pneumonia
- 1 February 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal Of Hypertension
- Vol. 28 (2), 401-405
- https://doi.org/10.1097/hjh.0b013e3283330948
Abstract
Objective To determine whether angiotensin-converting enzyme (ACE) inhibitors and other antihypertensives are associated with risk of pneumonia. Methods We conducted a nested case–control study of incident pneumonia in a subcohort of hypertensive adults insured by several large commercial plans throughout the United States. Individuals with pneumonia were matched on age, sex, region, and subscriber status with up to 10 controls free of pneumonia at the time of case diagnosis. We examined use of β-blockers, calcium channel blockers, ACE inhibitors (lipophilic and hydrophilic), angiotensin receptor blockers, and thiazides in the prior 3 and 12 months. Results A total of 7429 cases of pneumonia occurred among 305 958 hypertensive individuals. Risk of pneumonia was higher among users of β-blockers [adjusted odds ratio (OR) 1.11; 95% confidence interval (CI) 1.03–1.19], calcium channel blockers (adjusted OR 1.09, 95% CI 1.00–1.17), and lipophilic ACE inhibitors (adjusted OR 1.15, 95% CI 1.03–1.28) in the preceding 3 months; risks were also higher for use in the preceding 12 months. We observed lower risk with thiazide use in the preceding 3 months (adjusted OR 0.90, 95% CI 0.81–0.99) and hydrophilic ACE inhibitor use in the preceding year (adjusted OR 0.86, 95% CI 0.75–0.99). Conclusion In this population of middle-aged Americans with hypertension, we observed a modestly higher risk of pneumonia with use of β-blockers, calcium channel blockers, and lipophilic ACE inhibitors. These results are consistent with possible differences in noncardiovascular outcomes among users of antihypertensives and other commonly used cardiovascular drugs but require confirmation in other populations.Keywords
This publication has 29 references indexed in Scilit:
- Reassessing the Cardiovascular Risks and Benefits of ThiazolidinedionesClinical Cardiology, 2008
- Surrogate End Points and FDA ApprovalPublished by American Medical Association (AMA) ,2008
- Use of ACE inhibitors and risk of community-acquired pneumonia: a reviewEuropean Journal of Clinical Pharmacology, 2008
- Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritisRheumatology, 2007
- Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general populationEuropean Respiratory Journal, 2006
- Do Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Decrease the Risk of Hospitalization Secondary to Community-Acquired Pneumonia? A Nested Case-Control StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Angiotensin-Converting Enzyme Inhibitor-Induced CoughChest, 2006
- Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designsJournal of Clinical Epidemiology, 2005
- HOPE study impact on ACE inhibitors use.Annals of Pharmacotherapy, 2003
- Cough and ACE InhibitorsArchives of Internal Medicine, 1992